HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CIR Panel To Re-Review Cosmetic Preservative In Light Of New Allergy Data

This article was originally published in The Rose Sheet

Executive Summary

CIR’s Expert Panel decided at its March 19 meeting to re-review preservative methyisothiazolinone, taking into account new allergy data, after the substance was named “Contact Allergen of the Year” by the American Contact Dermatitis Society. Panel will also reopen reviews of hydroquinone and p-hydroxyanisole to consider the chemicals’ use in nail care.

You may also be interested in...

FDA Research Seeks Better Understanding Of Talc’s Potential Cancer Link

FDA’s Office of Cosmetics and Colors is heading up laboratory studies to explore an issue central to rampant litigation – talc’s effects on female genital system tissues, supported by a grant from the agency’s Office of Women’s Health. The agency is still finalizing a scientific literature review, but expects its research will help fill gaps that have not been adequately covered by epidemiologic and animal studies to date.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

FDA Gets Message In Congress' First Cannabis Policy Hearing: Deliver CBD Regulation

During first-ever congressional hearing on federal policies for lawful use of cannabis, House Energy and Commerce Health Subcommittee Chairwoman Anna Eschoo says with $2m appropriated to develop a regulation on CBD’s use in non-drug products during, FDA should deliver.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts